Second-line chemotherapy in small cell lung cancer
- 31 December 1990
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 17 (4) , 427-436
- https://doi.org/10.1016/0305-7372(90)90083-r
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16–213, doxorubicin and vincristine (VPAV) for small cell lung cancerEuropean Journal of Cancer and Clinical Oncology, 1988
- Cisplatin and Etoposide as Second-Line Chemotherapy in Patients with Small Cell Lung CancerCancer Investigation, 1988
- Reinduction chemotherapy in small cell lung cancerEuropean Journal of Cancer and Clinical Oncology, 1987
- Cyclophosphamide, Etoposide, and Infusion Cisplatin in Refractory Small Cell Lung CancerAmerican Journal of Clinical Oncology, 1987
- Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates.Journal of Clinical Oncology, 1986
- Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.Journal of Clinical Oncology, 1985
- Mitomycin-C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second-line regimen in lung cancerAmerican Journal of Clinical Oncology, 1984
- Cyclic alternating 'non-cross resistant' chemotherapy in the management of small cell anaplastic carcinoma of the lungCancer Treatment Reviews, 1984
- VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancerCancer, 1984
- Epipodophyllotoxin (VP16-213) in small cell carcinoma of the bronchus resistant to initial combination chemotherapyCancer Chemotherapy and Pharmacology, 1982